• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of European CME >Regulating for Bias in Medical Education – Reaction to the Pharmaceutical Industry Updated EFPIA Code of Practice
【24h】

Regulating for Bias in Medical Education – Reaction to the Pharmaceutical Industry Updated EFPIA Code of Practice

机译：调节医学教育偏见 - 对制药行业的反应更新了EFPIA的实践准则

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The European Federation of Pharmaceutical Industries and Associations (EFPIA) representing the pharmaceutical industry operating in Europe, introduced three codes of conduct between 2007 and 2013, which had a common goal of self-regulating interactions with healthcare professionals and patient organisations. This former set of rules was appreciated as a first self-regulatory step, although self-regulation itself is still considered by many stakeholders as insufficient to provide thorough transparency. EFPIA agreed to replace the separate codes with a new, consolidated EFPIA Code of Practice. The consolidated Code was broadened to include a new section on medical education that outlines the scope of member companies' engagement in "medical education activities?. This new section is controversial as it explicitly confirms that EFPIA members can be involved in medical education. In our view "independent Medical Education" per se prevents industry from "organising" events, i.e. industry must not influence content, presentation, choice of lecturers or publication of results. What is more, only events respecting this key principle (amongst others) can be recognised for purposes of continuing medical education/continuing professional development (CME/CPD). A substantial portion of the medical education is currently funded by the pharmaceutical and medical device industries. This practice carries a significant risk to public and personal health, especially if it is not adequately safeguarded by a high standard of accreditation. We are most concerned by the fact that EFPIA, representing the pharmaceutical industry, is trying to broaden the approach to medical education, to include activities that are not independently evaluated as free from undue influence and conflicts of interest. We believe that in order to preserve scientific integrity and independence, pharmaceutical companies must not be granted the right to influence the content of medical education.? 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
机译：欧洲制药行业和协会联合会（EFPIA）代表在欧洲经营的制药行业，在2007年至2013年期间推出了三种行为守则，这具有与医疗专业人士和患者组织进行自我调节互动的共同目标。作为第一个自我监管步骤，虽然许多利益相关者仍被认为是不足以提供全面的透明度的自我监管本身仍然被认为是第一个自我监管的一步。 EFPIA同意用新的综合的EFPIA惯例替换单独的代码。综合守则被扩大为包括关于医学教育的新部分，概述了“医学教育活动”的成员公司参与的范围概述了。这个新部分是有争议的，因为它明确证实了EFPIA成员可以参与医学教育。在我们的观看“独立医学教育”本身可防止行业从“组织”活动，即行业不得影响内容，演示，讲师选择或出版结果。更重要的是，只有尊重这个关键原则（其中）的事件，可以得到认可出于持续的医学教育/继续专业发展（CME / CPD）。专业的医学教育目前由制药和医疗器械行业提供资金。这种做法对公众和个人健康有重大风险，特别是如果是通过高标准的认可没有充分保护。我们最关心的是，EFPIA，谴责制药业正在努力拓宽医学教育的方法，包括没有独立评估的活动，没有免受过度影响和利益冲突。我们认为，为了保持科学的诚信和独立，制药公司不得授予影响医学教育内容的权利。 2019年作者。由Informa Informa Limited发布，贸易为泰勒和弗朗西斯集团。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号